Compare DLO & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLO | CORT |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | Uruguay | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 2021 | 2001 |
| Metric | DLO | CORT |
|---|---|---|
| Price | $11.24 | $72.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | $17.25 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 2.9M | 1.0M |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | $41.00 | $26.08 |
| Revenue Next Year | $26.98 | $26.98 |
| P/E Ratio | $22.27 | ★ N/A |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $9.75 | $28.66 |
| 52 Week High | $16.78 | $91.00 |
| Indicator | DLO | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 80.07 |
| Support Level | $10.90 | $68.20 |
| Resistance Level | $13.66 | $79.89 |
| Average True Range (ATR) | 0.53 | 2.57 |
| MACD | -0.03 | 0.87 |
| Stochastic Oscillator | 34.15 | 87.98 |
DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables world-wide enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company operates in a single operating segment, which is payment processing. The company's geographical segments include Latin America and Non-Latin America, with a majority of its revenue being generated from Brazil in the Latin America region.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.